PDT Partners LLC Takes $627,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

PDT Partners LLC purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 79,169 shares of the company's stock, valued at approximately $627,000.

A number of other large investors have also added to or reduced their stakes in AMRX. JPMorgan Chase & Co. lifted its holdings in Amneal Pharmaceuticals by 149.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company's stock worth $10,792,000 after buying an additional 777,568 shares during the period. Barclays PLC lifted its stake in Amneal Pharmaceuticals by 134.1% in the third quarter. Barclays PLC now owns 296,384 shares of the company's stock worth $2,466,000 after acquiring an additional 169,756 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Amneal Pharmaceuticals in the fourth quarter valued at $520,000. Amundi bought a new position in Amneal Pharmaceuticals in the 4th quarter worth $256,000. Finally, Franklin Resources Inc. lifted its position in shares of Amneal Pharmaceuticals by 4.9% in the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company's stock worth $778,000 after purchasing an additional 4,178 shares during the period. Institutional investors own 31.82% of the company's stock.

Wall Street Analyst Weigh In

AMRX has been the topic of several recent research reports. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Barclays increased their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a research note on Monday, March 3rd. Finally, StockNews.com raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Monday. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $11.50.

Amneal Pharmaceuticals Trading Up 0.6 %

NASDAQ:AMRX traded up $0.05 during mid-day trading on Wednesday, reaching $7.23. The company's stock had a trading volume of 481,056 shares, compared to its average volume of 1,420,635. The firm's fifty day moving average price is $7.98 and its two-hundred day moving average price is $8.15. Amneal Pharmaceuticals, Inc. has a 12-month low of $6.29 and a 12-month high of $9.48. The stock has a market cap of $2.24 billion, a P/E ratio of -10.60 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, May 2nd. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.14 by $0.05. The company had revenue of $695.42 million for the quarter, compared to the consensus estimate of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. Analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares in the company, valued at approximately $405,628,045.15. This trade represents a 9.33 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.